Press Releases
CDMO to invest over โฌ3m in GMP facility expansion
Spray drying specialist and capsule filling service provider Micro-Sphere is investing 3.5 million CHF (โฌ3.2 million) into expanding its GMP manufacturing capabilities and processes.
Micro-Sphere...
Press Releases
Sterling Pharma Solutions invests $1.5m into US facility expansion
Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, is investing $1.5m into a phased expansion of its US facility in North Carolina.
The...
News
The renewed Turkish Cargo Web Portal now offers you many conveniences with its new name โTK GOโ
Turkish Cargo, the fastest-growing brand of the global air cargo industry, updated its web portal; a functional and user-friendly interface on Internet facilitating monitoring...
News
FDA should withdraw ANDAsโ,and โnew technologies could bring massive improvements in efficiencyโ if implemented correctly
CPhI Worldwide โ the worldโs largest pharma event taking place in Frankfurt (5th-7th November 2019) โhas released the first part of its eponymous2019 Annual...
Drug Research
Shionogi and Hsiri to develop mycobacterial disease therapies
Japanese pharmaceutical firm Shionogi has signed a licence agreement with Hsiri Therapeutics for the discovery and development of therapies for non-tuberculous mycobacterial (NTM) diseases,...
News
TriPharm Services announces creation of pharmaceutical manufacturing center
TriPharm Services, a new contract development and manufacturing organization (CDMO), is commissioning a new specialized manufacturing operation utilizing the latest isolator manufacturing equipment.
The center...
News
Biocartis NV.: Biocartis Launches Liquid Biopsy Idylla ctEGFR Mutation Assay
Biocartis Group NV, an innovative molecular diagnostics company announces the launch of the Idylla ctEGFR Mutation Assay (RUO1). This assay is the liquid biopsy...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
















